(Q51034723)

English

Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases.

scientific article published on 27 April 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23624956

Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases. (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23624956

focal segmental glomerulosclerosis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Andreas Kronbichler

1

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23624956

5

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23624956

author name string

Paul König

2

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23624956

Martin Busch

3

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23624956

Gunter Wolf

4

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23624956

Michael Rudnicki

6

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23624956

publication date

27 April 2013

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23624956

Vienna Clinical Weekly

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23624956

125

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23624956

11-12

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23624956

328-333

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23624956

Adult minimal-change disease: clinical characteristics, treatment, and outcomes.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0366-7

21 January 2018

Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0366-7

21 January 2018

Adult-onset minimal change disease among Taiwanese: clinical features, therapeutic response, and prognosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0366-7

21 January 2018

Remission of proteinuria in primary glomerulonephritis: we know the goal but do we know the price?

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0366-7

21 January 2018

A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0366-7

21 January 2018

Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0366-7

21 January 2018

Experience with levamisole in frequently relapsing, steroid-dependent nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0366-7

21 January 2018

Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0366-7

21 January 2018

Rituximab in refractory nephrotic syndrome.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0366-7

21 January 2018

Efficacy and Safety of Treatment with Rituximab for Difficult Steroid-Resistant and -Dependent Nephrotic Syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0366-7

21 January 2018

Rituximab treatment for adults with refractory nephrotic syndrome: a single-center experience and review of the literature.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0366-7

21 January 2018

Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0366-7

21 January 2018

Prevention and treatment of systemic glucocorticoid side effects

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0366-7

21 January 2018

Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0366-7

21 January 2018

Rituximab (B-cell depleting antibody) associated lung injury (RALI): a pediatric case and systematic review of the literature.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0366-7

21 January 2018

Anti-CD20 antibody is an efficient therapeutic tool for the selective removal of autoreactive T cells

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0366-7

21 January 2018

Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0366-7

21 January 2018

Depletion of functionally active CD20+ T cells by rituximab treatment

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0366-7

21 January 2018

Treatment of focal segmental glomerulosclerosis with immunophilin modulation: when did we stop thinking about pathogenesis?

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0366-7

21 January 2018

Th2 cells predominate in idiopathic steroid-sensitive nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0366-7

21 January 2018

Successful use of single-dose rituximab for the maintenance of remission in a patient with steroid-resistant nephrotic syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/23624956

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of single-dose rituximab on primary glomerular diseases

1 reference

https://pubmed.ncbi.nlm.nih.gov/23624956

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab treatment for adult patients with focal segmental glomerulosclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23624956

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab for steroid-dependent nephrotic syndrome.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23624956

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of remission following a single dose of rituximab alone in a patient with minimal change nephrotic syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/23624956

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab in adult patients with immunosuppressive-dependent minimal change disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23624956

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis: report of four cases and review of the literature.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23624956

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations

1 reference

https://pubmed.ncbi.nlm.nih.gov/23624956

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00508-013-0366-7

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23624956

release_vmdr4ay5cncqro4t64ty27wmji

1 reference

https://api.fatcat.wiki/v0/release/vmdr4ay5cncqro4t64ty27wmji

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23624956

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51034723&oldid=2210655652"